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INTRODUCTION
Recent studies have reported that dysfunction of neuronal 
plasticity in the brain alters neuronal networks, resulting in 
depression.
1,2 Patients with depression show signs of morpho-
logical shrinkage, including reduced hippocampal volume, 
dendritic and synaptic atrophy and reduced adult neurogene-
sis in the brain.
3-5 This shrinkage can be treated with therapeu-
tic antidepressants, which can reverse such morphological 
180  Copyright © 2012 Korean Neuropsychiatric Association  
changes through neural remodeling mechanisms, such as the 
expression of cytoskeletal proteins, or through cell adhesion 
molecules, such as neural cell adhesion molecules (NCAM).
6-8 
The precise mechanism by which neural remodeling and the 
NCAM signaling pathway are regulated by antidepressants, 
however, is not well-known. 
NCAM, a cell adhesion molecule that is a member of the im-
munoglobulin superfamily, plays a significant role in neuronal 
development and synaptic plasticity.
9,10 NCAM is also involved 
in learning and memory in the adult brain.
9 NCAM can be modi-
fied by the addition of α-2,8-polysialic acid (PSA) and also has 
three major isoforms: NCAM120, NCAM140 and NCAM180. 
NCAM120 is an extracellular polypeptide that is attached to 
the cell surface, NCAM140 is located in migratory growth 
corns and NCAM180 is present at sites of cell-cell contact.
10 
NCAM activates signal transduction cascades through both ho-
mophilic and heterophilic interactions. Homophilic NCAM in-
teractions promote the binding of p59
fyn (non-receptor tyro-
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sine kinase) and p125
fak (focal adhesion kinase) and their 
phosphorylation, which activate the Ras-mitogen-activated pro-
tein kinase (MAPK) pathway. In turn, the cyclic-AMP response 
element binding protein (CREB) is subsequently phosphorylat-
ed, resulting in neurite outgrowth. Beggs et al.
11 showed that 
NCAM140 interacted with p59
fyn and p125
fak, suggesting that 
NCAM140 regulates the FAK-Fyn-Ras-MAPK pathway 
through a homophilic interaction. Schmid et al.
12 observed that 
the transfection of NCAM140 into rat B35 neuroblastoma cells 
resulted in NCAM140 clustering that transiently activated MAPK 
and induced an increase in phosphorylated CREB (pCREB). Jes-
sen et al.
13 observed that PC12-E2 cells that were transfected with 
a negatively interfering form of CREB did not show NCAM140-
stimulated neurite outgrowth. Taken together, these data indi-
cate that NCAM140 promotes the phosphorylation of CREB. 
As a result, pCREB, the activated form of CREB, is not only in-
volved in the promotion of neurite outgrowth,
10 but also in learn-
ing and long-term memory.
14
Some antidepressants increase the expression of NCAM or 
pCREB in parts of the brain.
8,15,16 Conboy et al.
8 showed that 
agomelatine, a melatonin receptor agonist and serotonin (5-HT) 
receptor antagonist, induced an increase of synaptic NCAM in 
the rat ventral hippocampus and blocked the predator stress-in-
duced impairment of spatial memory. Varea et al.
16 observed 
that chronic treatment with fluoxetine increased the levels of 
the polysialylated form of NCAM (PSA-NCAM) in the medial 
prefrontal cortex but decreased its levels in the amygdale of rats. 
Taken together, these results indicate that antidepressants dif-
ferentially regulate the expression of NCAM in different regions 
of the brain. The transcription factor CREB, which plays an im-
portant role in neuronal plasticity, can be phosphorylated in the 
rat medial prefrontal cortex and the piriform cortex by chronic 
treatment with the tricyclic antidepressant imipramine.
15 In ad-
dition, Laifeneld et al.
14 found that prolonged stress induced a 
decrease in pCREB in the hippocampus, prefrontal cortex and 
striatum of rats and that treatment with desipramine or fluox-
etine induced an increase of pCREB only in the prefrontal cor-
tex. These observations showed that these antidepressants reg-
ulate pCREB expression only in specific regions of the brain, 
such as the prefrontal cortex. Thus, synaptic plasticity could be 
improved in specific regions of the brain by the antidepressant-
induced increase in NCAM and pCREB expression. 
Fluoxetine, a selective 5-HT reuptake inhibitor, exhibits a 
strong antidepressive effect by blocking the 5-HT transporter 
(5-HTT), resulting in increased levels of available serotonin at 
the synapse.
17 Despite the almost immediate effect on 5-HTT 
levels at the synapse after its administration, the clinical effects 
of fluoxetine are only seen after a few weeks of treatment.
1 These 
delayed effects have been suggested to be associated with chang-
es in postreceptor signaling.
18,19 
To better understand how fluoxetine regulates molecules 
involved in neuronal plasticity, this study was designed to 
determine the effects of time-dependent fluoxetine treat-
ments on NCAM140 and pCREB in rat C6 glioma cells. C6 
cells, which have a high level of N-methyl-D-aspartate, do-
pamine D2 and glucocorticoid receptors, react to antidepres-
sants similarly in vivo and in vitro by directly down-regulat-
ing the monoamine receptor through the postsynaptic action 
of the antidepressants.
20,21 After the treatment of C6 cells with 
fluoxetine, immunocytochemistry was used to examine the 
distribution of NCAM and western blot analysis was used to 
determined the expression levels of NCAM140, CREB and 
pCREB over time.
 
METHODS
Cell culture and fluoxetine treatment
C6 cells (ATCC, Manassas, VA, USA) were cultured in DMEM 
(Invitrogen, Carlsbad, CA, USA) containing 10% FBS and 
penicillin (100 U/mL)/streptomycin (100 μg/mL) (P/S) at 37°C 
in humidified 5% CO2. For the experiments, the cells were seed-
ed at a density of 1×10
6 cells/100-mm culture dish. After 12 h, 
fresh medium containing fluoxetine (Eli Lilly Indianapolis, IN, 
USA) or 10% ethanol was added to the cell culture for the ex-
perimental or control cells, respectively. Ethanol was selected for 
the control because it was the solvent for the fluoxetine. For the 
fluoxetine group, the cells were incubated in fresh medium con-
taining 10 μM fluoxetine for 20 min or for 6, 24 or 72 h. The 10-
μM concentration of fluoxetine was selected for this study be-
cause it has been shown that apoptosis does not occur under 
this condition.
22,23 For the control group, the cells were incu-
bated in fresh medium containing 10% ethanol for 20 min or 
for 6, 24 or 72 h. These treatments were repeated six times. 
Immunocytochemistry
C6 cells were plated onto cover slips pre-coated with colla-
gen (Sigma-Aldrich, St. Louis, MO, USA) in DMEM contain-
ing 10% FBS and P/S and incubated at 37°C in humidified 5% 
CO2. After 12 h, fresh medium containing fluoxetine or 10% 
ethanol was added to the cell culture, and the cells were incubat-
ed for 24 or 72 h. After incubation, the cells were fixed in 4% 
paraformaldehyde for 20 min at room temperature and then in-
cubated in PBS containing 10% normal goat serum, 0.3% Tri-
ton X-100 and 0.1% bovine serum albumin (BSA) (Sigma-Al-
drich) for 30 min at room temperature. The cells were incubated 
with a polyclonal rabbit anti-NCAM antibody (1 : 2,000) (Chemi-
con, Temecula, CA, USA) overnight at 4°C, followed by a wash 
with PBS containing 0.1% BSA. Next, the cells were incubated 
with biotinylated anti-rabbit IgG (H+L) (1 : 200) (Vector Labo-
ratories, San Francisco, CA, USA) for 1 h, followed by a wash 182  Psychiatry Investig 2012;9:180-186
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with PBS containing 0.1% BSA. The cells were then incubated 
with a streptavidin-conjugated anti-rabbit antibody (1 : 400) 
(Vector Laboratories) in the dark for 1 h. The cells were placed 
in a mounting solution containing 4’-6-diamidino-2-phenylin-
dole (Vector Laboratories) and observed using a phase contrast 
microscope (Olympus, Tokyo, Japan).
 
Western blot analysis
Total protein extraction from cells was performed using the 
PRO-PREP
TM Protein Extraction Solution (iNtRON Biotech-
nology, Seongnam, Korea) according to the manufacturer’s in-
structions. The extracted proteins were separated by SDS-PAGE 
and transferred to PVDF membranes. The membranes were 
incubated overnight at 4°C with the polyclonal rabbit anti-
NCAM (1 : 10,000) (Chemicon), polyclonal rabbit anti-CREB 
(1 : 1,000) (Cell Signaling Technology, Danvers, MA, USA) and 
polyclonal rabbit anti-pCREB (1 : 1,000) (Cell Signaling Tech-
nology) antibodies, followed by incubation with HRP-conju-
gated anti-rabbit IgG (1 : 2,000). After washing in TBST, the re-
actions were visualized using ECL Plus Western Blotting Detection 
Reagents (Amersham Life Science, Buckinghamshire, UK). The 
concentration of NCAM140, CREB and pCREB was quantified 
using QuantityOne software (Bio-Rad Laboratories, Hercules, 
CA, USA).
Statistical analysis
The data were expressed as the mean ± standard error of mean 
(SEM) from six or more independent experiments. Statistical 
analyses were performed using SPSS 13.0 (SPSS Inc., Chicago, 
IL, USA). The data were tested using one-way ANOVAs followed 
by post hoc testing with Tukey’s honestly significant difference 
(HSD) test, and p-values<0.05 were considered significant.
RESULTS
Effect of fluoxetine on NCAM expression 
The effects of 24 h and 72 h fluoxetine treatment on NCAM 
expression in C6 cells are shown in Figure 1. The 24-h fluox-
etine treatment resulted in the distribution of NCAM both 
around the cell membrane and in the nucleus, whereas NCAM 
was primarily expressed in the nucleus and around the nuclear 
membrane in the control cells (Figure 1A). The 72-h treatment 
with fluoxetine caused significantly higher levels of NCAM to 
be localized to the cell membranes compared to the 24-h treat-
ed cells. There were no differences with respect to NCAM ex-
pression in the control cells when 24- and 72-h cultures were 
compared (Figure 1B). Based on these results and the fact that 
NCAM140 exists in freely moving growth cones,
11 the NCAM 
found in increased amounts around the cell membranes of 72-h 
fluoxetine-treated cells is likely to be NCAM140.
Effect of fluoxetine on NCAM140 expression 
After the cultivation of the fluoxetine-treated cells and the 4% 
ethanol-treated control cells for different lengths of time (20 
min and 6, 24 and 72 h), immunoblotting was used to detect 
the expression of NCAM140. Even after 72 h, the level of 
NCAM140 in the control cells did not increase (Figure 2A). In 
the fluoxetine-treated cells, the expression of NCAM140 in-
creased by more than 50% at 6 and 24 h and by almost 100% 
at 72 h when compared to that in the cells treated with fluoxetine 
for 20 min (Figure 2B). In particular, cells treated with fluoxetine 
for 6 (p=0.044) and 72 h (p=0.003) exhibited significant increas-
es of NCAM140 compared to cells treated for 20 min, suggest-
ing that a 72-h treatment with fluoxetine promotes neurite out-
growth via increased levels of NCAM140. In contrast, NCAM120 
NCAM NCAM Merged Merged A   B
Figure 1. Effect of fluoxetine on NCAM expression in rat C6 glioma cells. Cells were treated with 10 μM of fluoxetine for 24 or 72 h. After 
fixation, the cells were incubated with a polyclonal rabbit anti-NCAM antibody. A: NCAM distribution in control and fluoxetine-treated cells 
cultured for 24 h. B: NCAM distribution in control and fluoxetine-treated cells cultured for 72 h. Arrows show nuclei stained with DAPI. Mag-
nification: ×200. NCAM: neural cell adhesion molecules. Con: control, Flx: fluoxetine.MR Choi et al. 
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expression slightly decreased, and NCAM180 expression did 
not change in response to fluoxetine when compared to cells 
treated for 20 min (Figure 3).
Effect of fluoxetine on the expression and 
phosphorylation of CREB 
After the cultivation of the fluoxetine-treated and control cells 
for different lengths of time (20 min and 6, 24 and 72 h), immu-
noblotting was used to detect the expression and phosphoryla-
tion (pCREB) of CREB. At 72 h, the expression of CREB in the 
control cells was slightly increased compared to that at 20 min, 
although this increase was not statistically significant (Figure 
4A). In addition, the levels of pCREB in the control cells increased 
slightly at 24 and 72 h compared to that at 20 min; however, this 
increase was not statistically significant, and the intensity of the 
pCREB bands was generally faint at all time points tested (Fig-
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Figure 2. Effect of fluoxetine on NCAM140 expression in rat C6 glioma cells. Cells were treated with 10 μM of fluoxetine for 20 min or for 6, 
24 or 72 h. The expression of the NCAM140 protein was measured by western blot analysis, and actin was used as an internal control. A: 
Control cells. B: Fluoxetine-treated cells. The values of NCAM140 intensity are represented as the mean±SEM (n=6) of the percent change 
from 100% of the cells cultured for 20 min. *Significantly different from 20 min by a one-way ANOVA, followed by Tukey’s HSD post hoc test 
(*p<0.05). NCAM: neural cell adhesion molecules.
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Figure 3. Effect of fluoxetine on NCAM120 and NCAM180 expression in rat C6 glioma cells. Cells were treated with 10 μM of fluoxetine for 
20 min or for 6, 24 or 72 h. The expression of the NCAM120 and NCAM180 was measured by western blot analysis, and actin was used as 
an internal control. A: Control cells. B: Fluoxetine-treated cells. The values of NCAM120 and NCAM180 intensity are represented as the 
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ure 4A). In the fluoxetine-treated cells, the expression levels of 
CREB continuously decreased over time, with the amount of 
CREB at 24 (p=0.018) and 72 h (p=0.017) significantly lower than 
that at 20 min (Figure 4B). In contrast, although there was a slight 
decrease in pCREB in the fluoxetine-treated cells at 6 and 24 h 
compared to that at 20 min, the levels of pCREB in the fluox-
etine-treated cells at 72 h not only increased more than 60%, 
they were also significantly different (p<0.001) when compared 
to the other treatment times (Figure 4B). Taken together, these 
results suggest that fluoxetine promotes both the expression and 
phosphorylation of CREB. 
 
DISCUSSION
In response to stress, the brains of depressive patients show 
glucocorticoid hypersecretion or hyperactivity of the hypotha-
lamic-pituitary-adrenal axis, reduced hippocampal volume and 
dendritic remodeling. This response induces the destruction of 
synaptic plasticity.
24 The chronic administration of antidepres-
sants can reverse these dysfunctions.
25 To understand the chronic 
effects of antidepressants at the molecular and cellular levels, 
identifying the mechanisms by which antidepressants regulate 
the inhibition of neuronal damage and dendrite outgrowth is im-
portant. Therefore, the aim of this study was to determine the 
effects of fluoxetine on the expression of NCAM140 and pCREB, 
which both belong to the NCAM signaling pathway that regu-
lates neuronal remodeling. 
In cells treated with fluoxetine for 24 h, the expression level of 
NCAM was higher in both the nucleus and cytoplasm than that 
in the control cells, showing the possibility that fluoxetine pro-
moted the expression of NCAM. After a 72-h treatment with 
fluoxetine, NCAM was mainly localized to the cell membranes. 
In addition, the fluoxetine-induced increase in the levels of NCAM 
was time-dependent, as shown by the higher NCAM levels after 
the 72-h treatment compared to those after the 24-h treatment. 
Varea et al.
16 demonstrated that in vivo chronic treatment with 
fluoxetine increased the levels of PSA-NCAM in the medial 
prefrontal cortex at approximately the same rate that the levels 
of NCAM increased in the present study. Chronic treatment with 
imipramine, a tricyclic antidepressant, had also been reported 
to induce an increase of PSA-NCAM in the rat prelimbic cor-
tex.
15 In contrast, Fang et al.
26 reported that venlafaxine, a sero-
tonin and norepinephrine reuptake inhibitor, attenuated the in-
crease of NCAM in the hilus area of the mouse hippocampus. 
Taken together, these observations indicate that antidepressants 
may have different effects on NCAM expression in the brain that 
is region specific. 
A variety of NCAMs are generated by alternative splicing, 
with NCAM120, NCAM140 and NCAM180 being the major 
splice forms. On the neuronal cell surface, NCAM140 induces 
the phosphorylation of p125
fak and p59
fyn through NCAM140 
homophilic binding and subsequently activates the Ras-MAPK 
pathways. In turn, these two downstream effects result in an in-
creased amount of neurite outgrowth.
10 Previously, we demon-
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Figure 4. Effect of fluoxetine on CREB and pCREB expression. Cells were treated with 10 μM of fluoxetine for 20 min or for 6, 24 or 72 h. 
The expression of CREB and pCREB was measured by western blot analysis, and actin was used as an internal control. A: Control cells. B: 
Fluoxetine-treated cells. The values of CREB and pCREB intensity are represented as the mean±SEM (n=6) of the percent change from 
100% of the cells cultured for 20 min. *Significantly different from 20 min by a one-way ANOVA, followed by Tukey’s HSD post hoc test 
(*p<0.05). CREB: cyclic-AMP response element binding protein, pCREB: phosphorylated CREB.
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strated that chronic fluoxetine treatment promoted the mRNA 
expression of the NCAM140 variant in C6 cells.
27 In the pres-
ent study, the levels of NCAM140 protein were increased by fluox-
etine treatment over time, whereas in the control cells, NCAM140 
expression did not change over time. In particular, a 72-h treat-
ment with fluoxetine resulted in an increase of NCAM140 by 
more than 80% when compared to a single 20-min treatment 
with fluoxetine. In contrast, fluoxetine did not appear to affect 
the levels of NCAM120 or NCAM180. Wakabayashi et al.
28 
demonstrated that NCAM140 mRNA levels decreased in the 
peripheral blood cells of bipolar disorder patients during their 
depressive stage, suggesting that the level of NCAM140 is in-
volved in depression. Given that patients with major depression, 
bipolar disorder or schizophrenia have shown aberrant altera-
tions of structural and synaptic plasticity such as dendritic or 
spine remodeling and that those dysfunctions could be normal-
ized by antidepressants, our data suggest that the synaptic plas-
ticity regulated by fluoxetine is controlled via the NCAMs, es-
pecially the NCAM140 isoform. Thus, fluoxetine treatment in 
C6 cells facilitates the expression of NCAM140 but not that of 
either NCAM120 or NCAM180, suggesting that fluoxetine may 
regulate synaptic plasticity via NCAM140. 
The transcriptional activity of CREB depends on its phos-
phorylation state, which results in the activation of cAMP re-
sponse element-mediated gene transcription and neuronal re-
modeling such as neurite outgrowth.
29 Some studies have de-
monstrated that fluoxetine treatment increases the phospho-
rylation of CREB.
19,30 Thome et al.
19 observed an increase of 
pCREB in several mouse brain regions, including the cerebral 
cortex, amygdala and hypothalamus after chronic but not acute 
treatment with fluoxetine. Mato et al.
30 reported that chronic 
fluoxetine treatment induced the up-regulation of pCREB in the 
rat prefrontal cortex. In the present study, the 6- and 24-h treat-
ment of C6 cells with 10 μM of fluoxetine showed a tendency to 
slightly decrease the levels of pCREB, whereas the 72-h treatment 
induced a significant increase in pCREB expression. Fluoxetine 
treatment for 72 h also decreased the expression of CREB, sug-
gesting that the effect of fluoxetine on pCREB is distinct from 
its effect on CREB, which may involve a negative regulatory pa-
thway or no interaction at all. Based on previous studies
19,30 
and the results herein, the concentration of fluoxetine is assumed 
to be important with respect to its ability to increase pCREB 
levels, with fluoxetine treatment leading to increased pCREB 
both in vivo and in vitro. 
In summary, fluoxetine treatment increased the levels of 
NCAM in rat C6 glioma cells. In particular, NCAM140, one of 
the NCAM major isoforms, was up-regulated by fluoxetine treat-
ment. Furthermore, pCREB, which is a down-stream transcrip-
tion factor in the Ras-MAPK pathway, was also increased by 
fluoxetine treatment. Taken together, the findings herein and 
those reported in previous studies
12,13 suggest that fluoxetine treat-
ment regulates neuronal plasticity and neurite outgrowth by phos-
phorylating and activating CREB via the NCAM140 homophil-
ic interaction-induced activation of the Ras-MAPK pathway 
and we illustrated the mechanism by which fluoxetine regulates 
the NCAM140 homophilic interaction (schematic diagram 
shown in Figure 5). In addition, these increases may account for 
the delay in therapeutic response to antidepressants at the mo-
lecular, biological and pharmacological levels. Although the in 
vitro up-regulation of the NCAM140 protein by fluoxetine was 
Figure 5. Schematic diagram showing 
the influence of fluoxetine on NCAM140 
homophilic interaction-induced activa-
tion of Ras-MAPK pathway. This path-
way is described based on the summa-
rized western blot data and previous 
studies
10,19,27,30 mentioned in the text. 
MAPK: mitogen-activated protein kinase, 
CREB: cAMP response element-binding.186  Psychiatry Investig 2012;9:180-186
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described for the first time in this study, the findings reported 
here must be reviewed in the context of the study’s limitations. 
Since antidepressant treatment was not performed in the serum-
free conditions comparable with stressful conditions in vitro, we 
are unable to exclude that antidepressant might regulate other 
isoforms of NCAM except for NCAM140 in the serum-free con-
ditions. Another methodological issue is the pCREB expres-
sion in the control cells. Although we have performed the ex-
periments six times to obtain pCREB immunoblot data in the 
control cells, the additional study could be done until they are 
proven to be sufficient. Therefore, further research should be 
performed to resolve these limitations. 
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